REG - Smith & Nephew Plc - Director/PDMR Shareholding

Smith & NephewAnnouncement

17/03/2021 15:30

RNS Number : 6133S
  
Smith & Nephew Plc
  
17 March 2021
  
 

SMITH & NEPHEW PLC
 
17 March 2021 
 
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM.
 
Following the announcement on 9 March 2021, regarding the awards made under the Smith & Nephew Global Share Plan 2020 of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company"), those share awards vested on 16 March 2021.  
 
1.       FINAL VESTING ON 16 MARCH 2021 OF SUPPLEMENTARY AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020 FOR THE 2018 PERFORMANCE SHARE PROGRAMME AWARDS: 
 
The awards were granted under the Global Share Plan 2020 on 8 March 2021. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. 
 
The following relates to all individuals included in the below notification:
 



Reason for the notification




Initial notification /Amendment


Initial notification




Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




Name


Smith & Nephew plc




LEI


213800ZTMDN8S67S1H61




Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




Description of the financial instrument, type of instrument
 


Smith & Nephew plc ordinary shares of USD 0.20 each
 




Identification code


ISIN: GB0009223206




Nature of the transaction


Final vesting on 16 March 2021 of Supplementary Awards granted under the Smith & Nephew Global Share Plan 2020 for the 2018 Performance Share Programme awards.




Date of Transaction


2021 - 03 - 16




Place of Transaction


London Stock Exchange (XLON)



 



Name
(Position) 


Status


Price (£)


Volume


Aggregated information


Total Ordinary Share Holding following the transaction *


Total Ordinary Share Holding as a % of the Company's ISC following the transaction *




Bradley Cannon
(President Sports Medicine & ENT)


PDMR


14.0000
 


3,740 (of which 1,665 were sold and 2,075 retained)


N/A Single Transaction


84,165.76313 ordinary shares (including 2,101.64550 in ADS')


0.00951%
 




Phil Cowdy
(Chief Business Development & Corporate Affairs Officer)


PDMR


14.0000
 


1,781 (of which 841 were sold and 940 retained)


N/A Single Transaction


45,298.19975 ordinary shares


0.00512%
 




Elga Lohler
(Chief HR Officer)


PDMR


14.0000
 


2,848 (of which 1,125 were sold and 1,723 retained)


N/A Single Transaction


106,816.00000 ordinary shares (including 3,015.00000 in ADS')


0.01207%
 




Catheryn O'Rourke
(Chief Legal & Compliance Officer) 


PDMR


14.0000
 


2,823 (of which 963 were sold and 1,860 retained)


N/A Single Transaction


81,517.23565 ordinary shares (including 5,818.25734 in ADS')


0.00921%
 




Vasant Padmanabhan
(President Research & Development) 


PDMR


14.0000
 


3,207 (of which 1,089 were sold and 2,118 retained)


N/A Single Transaction


64,620.00000 ordinary shares


0.00730%
 




Susan Swabey
(Company Secretary)


PDMR


14.0000
 


1,255 (of which 592 were sold and 663 retained)


N/A Single Transaction


49,225.83952 ordinary shares


0.00556%
 



 
* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.
 
Vickie Reuben  
Deputy Company Secretary
Smith & Nephew plc
 
Tel:  +44 (0)1923 477410
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHFLFLEVTIDLIL